Iron-induced oxidative stress in haemodialysis patients: A pilot study on the impact of diabetes

BioMetals

Volumn 21, Issue 2, 2008, Pages 159-170

  Van Campenhout, Ann ^a   Van Campenhout, Christel ^b   Lagrou, Albert ^c   Manuel Y Keenoy, Begoña ^c  

^a JAMES COOK UNIVERSITY   (Australia)

^b SCIENTIFIC INSTITUTE OF PUBLIC HEALTH   (Belgium)

^c UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

Diabetes; Haemodialysis; Iron; Oxidative stress

Indexed keywords

FERRITIN; IRON; MALONALDEHYDE; TRANSFERRIN;

ADULT; AGED; ANTIOXIDANT ACTIVITY; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETES MELLITUS; FEMALE; HEMODIALYSIS; HUMAN; IRON BLOOD LEVEL; IRON STORAGE; KIDNEY FAILURE; LIPID PEROXIDATION; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PILOT STUDY; PROTEIN GLYCOSYLATION;

ADULT; AGED; AGED, 80 AND OVER; ANTIOXIDANTS; BLOOD CHEMICAL ANALYSIS; DIABETES MELLITUS; FEMALE; FERRITINS; HUMANS; IRON; LIPID PEROXIDATION; MALE; MALONDIALDEHYDE; MIDDLE AGED; OXIDATIVE STRESS; PILOT PROJECTS; RENAL DIALYSIS;

EID: 41049107112     PISSN: 09660844     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10534-007-9104-9     Document Type: Article

References (48)

1. Anraku M, Kitamura K, Shinohara A et al (2004) Intravenous iron administration induces oxidation of serum albumin in hemodialysis patients. Kidney Int 66:841-848
2. Baynes JW (1991) Role of oxidative stress in development of complications in diabetes. Diabetes 40:405-412
3. Beutler E (1975) Reduced glutathione (GSH). In: Beutler E (ed) Red cell metabolism; a manual of biochemical methods. Grune & Stratton Inc., Orland FL, pp 131-132
4. Breuer W, Cabantchik ZI (2001) A fluorescence-based one-step assay for serum non-transferrin-bound iron. Anal Biochem 299:194-202
5. Breuer W, Ronson A, Slotki IN et al (2000) The assessment of serum nontransferrin-bound iron in chelation therapy and iron supplementation. Blood 95:2975-2982
6. Brownlee M (2005) The pathobiology of diabetic complications: a unifying mechanism. Diabetes 54:1615-1625
7. Caye-Vaugien C, Krempf M, Lamarche P, Charbonnel B, Pieri J (1990) Determination of a-tocopherol in plasma, platelets and erythrocytes of type I and type II diabetic patients by HPLC. Int J Vitam Nutr Res 60:324-330
8. Ceballos-Picot I, Witko-Sarsat V, Merad-Boudia M et al (1996) Glutathione antioxidant system as a marker of oxidative stress in chronic renal failure. Free Radic Biol Med 21:845-853
9. Dasgupta A, Hussain S, Ahmad S (1992) Increased lipid peroxidation in patients on maintenance hemodialysis. Nephron 60:56-59
10. Esposito BP, Breuer W, Slotki I, Cabantchik ZI (2002) Labile iron in parenteral iron formulations and its potential for generating plasma nontransferrin-bound iron in dialysis patients. Eur J Clin Invest 32(Suppl 1):42-49
11. Friedlander MA, Wu YC, Schulak JA, Monnier VM, Hricik DE (1995) Influence of dialysis modality on plasma and tissue concentrations of pentosidine in patients with end-stage renal disease. Am J Kidney Dis 25:445-451
12. Gutteridge JM, Quinlan GJ (1992) Antioxidant protection against organic and inorganic oxygen radicals by normal human plasma: the important primary role for iron-binding and iron-oxidising proteins. Biochim Biophys Acta 1159:248-254
13. Gutteridge JM, Rowley DA, Halliwell B (1982) Superoxide-dependent formation of hydroxyl radicals and lipid peroxidation in the presence of iron salts. Detection of 'catalytic' iron and anti-oxidant activity in extracellular fluids. Biochem J 206:605-609
14. Hall ND, Blake DR, Bacon PA (1982) Serum sulphydryl levels in early synovitis. J Rheumatol 9:593-596
15. Henle T, Deppisch R, Beck W et al (1999) Advanced glycated end-products (AGE) during haemodialysis treatment: discrepant results with different methodologies reflecting the heterogeneity of AGE compounds. Nephrol Dial Transplant 14:1968-1975
16. Himmelfarb J, Lazarus JM, Hakim R (1991) Reactive oxygen species production by monocytes and polymorphonuclear leukocytes during dialysis. Am J Kidney Dis 17:271-276
17. Johnson RN, Metcalf PA, Baker JR (1983) Fructosamine: a new approach to the estimation of serum glycosylprotein. An index of diabetic control. Clin Chim Acta 127:87-95
18. Jones CA, Krolewski AS, Rogus J et al (2005) Epidemic of end-stage renal disease in people with diabetes in the United States population: do we know the cause? Kidney Int 67:1684-1691
19. Kooistra MP, Kersting S, Gosriwatana I et al (2002) Nontransferrin-bound iron in the plasma of haemodialysis patients after intravenous iron saccharate infusion. Eur J Clin Invest 32(Suppl 1):36-41
20. Koschinsky T, He CJ, Mitsuhashi T et al (1997) Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy. Proc Natl Acad Sci USA 94:6474-6479
21. Lim PS, Wei YH, Yu YL, Kho B (1999) Enhanced oxidative stress in haemodialysis patients receiving intravenous iron therapy. Nephrol Dial Transplant 14:2680-2687
22. Lissi E, Salim-Hanna M, Pascual C, del Castillo MD (1995) Evaluation of total antioxidant potential (TRAP) and total antioxidant reactivity from luminol-enhanced chemiluminescence measurements. Free Radic Biol Med 18:153-158
23. Loughrey CM, Young IS, Lightbody JH et al (1994) Oxidative stress in haemodialysis. QJM 87:679-683
24. Luciak M, Trznadel K (1991) Free oxygen species metabolism during haemodialysis with different membranes. Nephrol Dial Transplant 6(Suppl 3):66-70
25. Macdougall IC, Tucker B, Thompson J et al (1996) A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int 50:1694-1699
26. Mimic-Oka J, Savic-Radojevic A, Pljesa-Ercegovac M et al (2005) Evaluation of oxidative stress after repeated intravenous iron supplementation. Ren Fail 27:345-351
27. Miyata T, Maeda K, Kurokawa K, van Ypersele DS (1997a) Oxidation conspires with glycation to generate noxious advanced glycation end products in renal failure. Nephrol Dial Transplant 12:255-258
28. Miyata T, Wada Y, Cai Z et al (1997b) Implication of an increased oxidative stress in the formation of advanced glycation end products in patients with end-stage renal failure. Kidney Int 51:1170-1181
29. Muller C, Eisenbrand G, Gradinger M et al (2004) Effects of hemodialysis, dialyser type and iron infusion on oxidative stress in uremic patients. Free Radic Res 38:1093-1100
30. Nielsen F, Mikkelsen BB, Nielsen JB, Andersen HR, Grandjean P (1997) Plasma malondialdehyde as biomarker for oxidative stress: reference interval and effects of life-style factors. Clin Chem 43:1209-1214
31. Odetti P, Cosso L, Pronzato MA, Dapino D, Gurreri G (1995) Plasma advanced glycosylation end-products in maintenance haemodialysis patients. Nephrol Dial Transplant 10:2110-2113
32. Papanastasiou P, Grass L, Rodela H et al (1994) Immunological quantification of advanced glycosylation end-products in the serum of patients on hemodialysis or CAPD. Kidney Int 46:216-222
33. Paul JL, Sall ND, Soni T et al (1993) Lipid peroxidation abnormalities in hemodialyzed patients. Nephron 64:106-109
34. Peuchant E, Carbonneau MA, Dubourg L et al (1994) Lipoperoxidation in plasma and red blood cells of patients undergoing haemodialysis: vitamins A, E, and iron status. Free Radic Biol Med 16:339-346
35. Salahudeen AK, Oliver B, Bower JD, Roberts LJ (2001) Increase in plasma esterified F2-isoprostanes following intravenous iron infusion in patients on hemodialysis. Kidney Int 60:1525-1531
36. Sengoelge G, Rainer V, Kletzmayr J et al (2004) Dose-dependent effect of parenteral iron therapy on bleomycin-detectable iron in immune apheresis patients. Kidney Int 66:295-302
37. Sunder-Plassmann G, Horl WH (1995) Importance of iron supply for erythropoietin therapy. Nephrol Dial Transplant 10:2070-2076
38. Sunder-Plassmann G, Horl WH (1996) Safety of intravenous injection of iron saccharate in haemodialysis patients. Nephrol Dial Transplant 11:1797-1802
39. Toborek M, Wasik T, Drozdz M et al (1992) Effect of hemodialysis on lipid peroxidation and antioxidant system in patients with chronic renal failure. Metabolism 41:1229-1232
40. USRDS (1997) Patient mortality and survival. United State Renal Data System. Am J Kidney Dis 30:S86-S106
41. Van Campenhout A, Van Campenhout CM, Lagrou AR, Manuel-y-Keenoy B (2003) Transferrin modifications and lipid peroxidation: implications in diabetes mellitus. Free Radic Res 37:1069-1077
42. Van Campenhout A, Van Campenhout CM, Lagrou AR, Moorkens G, De Block C, Manuel-y-Keenoy B (2006a) Iron-binding antioxidant capacity is impaired in diabetes mellitus. Free Rad Biol Med 40:1749-1755
43. Van Campenhout A, Van Campenhout C, Olyslager YS, Van Damme O, Lagrou AR, Manuel-y-Keenoy B (2006b) A novel method to quantify in vivo transferrin glycation: applications in diabetes mellitus. Clin Chim Acta 370:115-123
44. Washko PW, Hartzell WO, Levine M (1989) Ascorbic acid analysis using high-performance liquid chromatography with coulometric electrochemical detection. Anal Biochem 181:276-282
45. Yoshimura K, Nakano H, Yokoyama K, Nakayama M (2005) High iron storage levels are associated with increased DNA oxidative injury in patients on regular hemodialysis. Clin Exp Nephrol 9:158-163
46. Zager RA, Johnson AC, Hanson SY (2004) Parenteral iron nephrotoxicity: potential mechanisms and consequences. Kidney Int 66:144-156
47. Zager RA, Johnson AC, Hanson SY, Wasse H (2002) Parenteral iron formulations: a comparative toxicologic analysis and mechanisms of cell injury. Am J Kidney Dis 40:90-103
48. Zanen AL, Adriaansen HJ, van Bommel EF, Posthuma R, Th de Jong GM (1996) 'Oversaturation' of transferrin after intravenous ferric gluconate (Ferrlecit(R)) in haemodialysis patients. Nephrol Dial Transplant 11:820-824